Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients - Planchard, D; Mazieres, J; Riely, G J (J Clin Oncol, 2013)
Abstr 8009